JP2012521405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521405A5 JP2012521405A5 JP2012501411A JP2012501411A JP2012521405A5 JP 2012521405 A5 JP2012521405 A5 JP 2012521405A5 JP 2012501411 A JP2012501411 A JP 2012501411A JP 2012501411 A JP2012501411 A JP 2012501411A JP 2012521405 A5 JP2012521405 A5 JP 2012521405A5
- Authority
- JP
- Japan
- Prior art keywords
- dioxo
- pyrimidin
- acetamide
- dimethyl
- thiazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 chloro, bromo, methyl Chemical group 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 7
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 5
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 150000005347 biaryls Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- PYQZVIOQEOMABN-UHFFFAOYSA-N n-[4-[2,3-difluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-2-(5,7-dimethyl-4,6-dioxo-[1,2]thiazolo[5,4-d]pyrimidin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2SN=C1CC(=O)NC(SC=1)=NC=1C1=CC=C(C(F)(F)F)C(F)=C1F PYQZVIOQEOMABN-UHFFFAOYSA-N 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000014242 psoriasis 13 Diseases 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- UWAXMUSNRIUHRQ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(Cl)C(Cl)=CC=2)=C1 UWAXMUSNRIUHRQ-UHFFFAOYSA-N 0.000 description 1
- SDIUFDASQXZLBJ-UHFFFAOYSA-N 4-[4-(difluoromethoxy)-3,5-difluorophenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(F)C(OC(F)F)=C(F)C=2)=C1 SDIUFDASQXZLBJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665/MUM/2009 | 2009-03-23 | ||
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| US61/171,355 | 2009-04-21 | ||
| PCT/IB2010/000834 WO2010109328A1 (en) | 2009-03-23 | 2010-03-22 | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521405A JP2012521405A (ja) | 2012-09-13 |
| JP2012521405A5 true JP2012521405A5 (enExample) | 2013-04-18 |
Family
ID=42236291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501411A Withdrawn JP2012521405A (ja) | 2009-03-23 | 2010-03-22 | Ｔｒｐａ１調節因子としてのイソチアゾロピリミジンジオン誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8575178B2 (enExample) |
| EP (1) | EP2411397B1 (enExample) |
| JP (1) | JP2012521405A (enExample) |
| KR (1) | KR20120001746A (enExample) |
| CN (1) | CN102395592A (enExample) |
| AP (1) | AP2011005888A0 (enExample) |
| AU (1) | AU2010227224A1 (enExample) |
| BR (1) | BRPI1009372A2 (enExample) |
| CA (1) | CA2756534A1 (enExample) |
| DK (1) | DK2411397T3 (enExample) |
| EA (1) | EA201190191A1 (enExample) |
| ES (1) | ES2424340T3 (enExample) |
| IL (1) | IL215179A0 (enExample) |
| MX (1) | MX2011009821A (enExample) |
| PE (1) | PE20120764A1 (enExample) |
| PL (1) | PL2411397T3 (enExample) |
| PT (1) | PT2411397E (enExample) |
| SG (2) | SG174403A1 (enExample) |
| SI (1) | SI2411397T1 (enExample) |
| UA (1) | UA107342C2 (enExample) |
| WO (1) | WO2010109328A1 (enExample) |
| ZA (1) | ZA201107646B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2411393B1 (en) | 2009-03-23 | 2014-01-22 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as trpa1 modulators |
| CA2756535A1 (en) | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| EP2655377B1 (en) | 2010-12-20 | 2016-03-30 | Glenmark Pharmaceuticals S.A. | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| CA2836856A1 (en) * | 2011-06-13 | 2012-12-20 | Glenmark Pharmaceuticals, S.A. | Treatment of respiratory disorders using trpa1 antagonists |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| BR112013031820A2 (pt) | 2011-06-22 | 2016-12-13 | Glenmark Pharmaceutical S A | composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar |
| WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| CA2857109A1 (en) | 2011-12-05 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| MX354014B (es) | 2012-06-08 | 2018-02-08 | Glenmark Pharmaceuticals Sa | Amidas de compuestos de 2-amino-4-ariltiazol y sus sales. |
| AU2013326429B2 (en) | 2012-10-01 | 2017-10-26 | Orion Corporation | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists |
| JP2016504988A (ja) | 2012-11-14 | 2016-02-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | イミダゾピリジン誘導体 |
| AU2014282762B2 (en) | 2013-06-20 | 2016-11-10 | Ichnos Sciences SA | Nanoparticulate formulation comprising a TRPA1 antagonist |
| RU2016115093A (ru) | 2013-10-15 | 2017-11-21 | Гленмарк Фармасьютикалс С.А. | Фармацевтическая композиция, содержащая антагонист trpa1 и анальгетический агент |
| WO2015155306A1 (en) * | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018233648A1 (zh) * | 2017-06-21 | 2018-12-27 | 南京明德新药研发股份有限公司 | 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物 |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) * | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004055054A1 (en) | 2002-12-18 | 2004-07-01 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| EP1713815A4 (en) * | 2004-02-11 | 2009-03-11 | Smithkline Beecham Corp | PTH AGONISTS |
| WO2005089206A2 (en) | 2004-03-13 | 2005-09-29 | Irm Llc | Modulators of ion channel trpa1 |
| WO2006083005A1 (ja) | 2005-02-03 | 2006-08-10 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
| ES2436225T3 (es) | 2005-12-22 | 2013-12-27 | Hydra Biosciences, Inc. | Inhibidores TRPA1 para tratamiento del dolor |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| CL2008000252A1 (es) | 2007-01-29 | 2008-03-14 | Xenon Pharmaceuticals Inc | Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir |
| EP3663295A1 (en) * | 2007-06-22 | 2020-06-10 | Eli Lilly And Co. | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2010
- 2010-03-22 PL PL10716049T patent/PL2411397T3/pl unknown
- 2010-03-22 EA EA201190191A patent/EA201190191A1/ru unknown
- 2010-03-22 JP JP2012501411A patent/JP2012521405A/ja not_active Withdrawn
- 2010-03-22 PT PT107160491T patent/PT2411397E/pt unknown
- 2010-03-22 ES ES10716049T patent/ES2424340T3/es active Active
- 2010-03-22 CA CA2756534A patent/CA2756534A1/en not_active Abandoned
- 2010-03-22 DK DK10716049.1T patent/DK2411397T3/da active
- 2010-03-22 US US13/257,241 patent/US8575178B2/en not_active Expired - Fee Related
- 2010-03-22 BR BRPI1009372A patent/BRPI1009372A2/pt not_active IP Right Cessation
- 2010-03-22 PE PE2011001703A patent/PE20120764A1/es not_active Application Discontinuation
- 2010-03-22 AP AP2011005888A patent/AP2011005888A0/xx unknown
- 2010-03-22 KR KR1020117023383A patent/KR20120001746A/ko not_active Withdrawn
- 2010-03-22 EP EP10716049.1A patent/EP2411397B1/en not_active Not-in-force
- 2010-03-22 SG SG2011066495A patent/SG174403A1/en unknown
- 2010-03-22 MX MX2011009821A patent/MX2011009821A/es unknown
- 2010-03-22 WO PCT/IB2010/000834 patent/WO2010109328A1/en not_active Ceased
- 2010-03-22 CN CN2010800168801A patent/CN102395592A/zh active Pending
- 2010-03-22 SI SI201030232T patent/SI2411397T1/sl unknown
- 2010-03-22 AU AU2010227224A patent/AU2010227224A1/en not_active Abandoned
- 2010-03-22 SG SG2012069464A patent/SG184766A1/en unknown
- 2010-03-23 UA UAA201111149A patent/UA107342C2/ru unknown
-
2011
- 2011-09-15 IL IL215179A patent/IL215179A0/en unknown
- 2011-10-19 ZA ZA2011/07646A patent/ZA201107646B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521405A5 (enExample) | ||
| JP2012521401A5 (enExample) | ||
| MX2011009821A (es) | Derivados de isotiazolo pirimidinadiona como moduladores del trpa1. | |
| MX2011009822A (es) | Derivados de tienopirimidinadiona como moduladores del trpa1. | |
| AU2013276191B2 (en) | Triazolone compounds as mPGES-1 inhibitors | |
| CA2558585A1 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| JP5085659B2 (ja) | Ｌ−ｃｐｔ１阻害剤として有用なインダゾール誘導体 | |
| JP5746185B2 (ja) | 三置換１ｈ−ピロール類と、芳香族スペーサーおよびヘテロ芳香族スペーサーとに同時に基づく新規ヒストンデアセチラーゼ阻害剤 | |
| RU2010109881A (ru) | Способ получения производных 5-галогеналкил-4,5-дигидроизоксазола | |
| WO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| WO2012027965A1 (en) | Novel compounds | |
| WO2012100732A1 (en) | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof | |
| JP2010536767A5 (enExample) | ||
| JP2010513283A5 (enExample) | ||
| CA2396824A1 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| ZA200404742B (en) | Thiazole derivatives having CB1-antagonistic or partial agonistic activity. | |
| JP2006526656A5 (enExample) | ||
| JP2011500513A5 (enExample) | ||
| CA2415331A1 (en) | Beta3 adrenergic agonists | |
| WO2008038955A1 (en) | Benzophenone derivatives useful for inhibiting formation of microtubule | |
| JP2013506637A5 (enExample) | ||
| RU2015132105A (ru) | Азоловые производные бензола | |
| MX2011001678A (es) | Compuestos de azetidinas polisustituidos, su preparacion y aplicacion terapeutica. | |
| JP4939226B2 (ja) | チアゾール環を含むカルボン酸誘導体およびその医薬用途 | |
| Beck et al. | Nonaqueous diazotization of 5‐amino‐1‐aryl‐1H‐pyrazole‐4‐carboxylate esters |